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A B S T R A C T
Background
Traditional monitoring of ovarian hyperstimulation during in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI)
treatment has included transvaginal ultrasonography (TVUS) plus serum estradiol levels to ensure safe practice by reducing the incidence
and severity of ovarian hyperstimulation syndrome (OHSS) whilst achieving the good ovarian response needed for assisted reproduction
treatment. The need for combined monitoring (using TVUS and serum estradiol) during ovarian stimulation in assisted reproduction
is controversial. It has been suggested that combined monitoring is time consuming, expensive and inconvenient for women and that
simplification of IVF and ICSI therapy by using TVUS only should be considered.
Objectives
To assess the effect of monitoring controlled ovarian hyperstimulation (COH) in IVF and ICSI cycles in subfertile couples with TVUS
only versus TVUS plus serum estradiol concentration, with respect to rates of live birth, pregnancy and OHSS.
Search methods
We searched the Menstrual Disorders and Subfertility Group Specialised Register of controlled trials, the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO, the National Research Register, and web-based trial
registers such as Current Controlled Trials. The last search was conducted in May 2014. There was no language restriction applied. All
references in the identified trials and background papers were checked and authors were contacted to identify relevant published and
unpublished data.
Selection criteria
Only randomised controlled trials that compared monitoring with TVUS only versus TVUS plus serum estradiol concentrations in
women undergoing COH for IVF and ICSI treatment were included.
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Data collection and analysis
Three review authors independently selected the studies, extracted data and assessed risk of bias. They resolved disagreements by
discussion with the rest of the authors. Outcomes data were pooled and summary statistics were presented when appropriate. The
quality of the evidence was rated using the GRADE methods.
Main results
With this update, four new studies were identified resulting in a total of six trials including 781 women undergoing monitoring of
COH with either TVUS alone or a combination of TVUS and serum estradiol concentration during IVF or ICSI treatment.
None of the six studies reported our primary outcome of live birth rate. Pooled data showed no evidence of a difference in clinical
pregnancy rate per woman between monitoring with TVUS only and combined monitoring (odds ratio (OR) 1.10; 95% confidence
interval (CI) 0.79 to 1.54; four studies; N = 617; I² = 5%; low quality evidence). This suggests that compared with women with a 34%
chance of clinical pregnancy using monitoring with TVUS plus serum estradiol, the clinical pregnancy rate in women using TVUS
only was between 29% and 44%.
There was no evidence of a difference between the groups in the reported cases of OHSS (OR 1.03; 95% CI 0.48 to 2.20; six studies;
N = 781; I² = 0%; low quality evidence), suggesting that compared with women with a 4% chance of OHSS using monitoring with
TVUS plus serum estradiol, the OHSS rate in women monitored by TVUSS only was between 2% and 8%.
There was no evidence of a difference between the groups in the mean number of oocytes retrieved pre woman (mean difference (MD)
0.32; 95% CI -0.60 to 1.24; five studies; N = 596; I² = 17%; low quality evidence).
The evidence was low quality for all comparisons. Limitations included imprecision and potential bias due to unclear randomisation
methods, allocation concealment and blinding, as well as differences in treatment protocols. Quality assessment was hampered by the
lack of methodological descriptions in several studies.
Authors’ conclusions
This review update found no evidence from randomised trials to suggest that combined monitoring by TVUS and serum estradiol is
more efficacious than monitoring by TVUS alone with regard to clinical pregnancy rates and the incidence of OHSS. The number of
oocytes retrieved appeared similar for both monitoring protocols. The data suggest that both these monitoring methods are safe and
reliable. However, these results should be interpreted with caution because the overall quality of the evidence was low. Results were
compromised by imprecision and poor reporting of study methodology. A combined monitoring protocol including both TVUS and
serum estradiol may need to be retained as precautionary good clinical practice and as a confirmatory test in a subset of women to
identify those at high risk of OHSS. An economic evaluation of the costs involved with the two methods and the views of the women
undergoing cycle monitoring would be welcome.
P L A I N L A N G U A G E S U M M A R Y
Monitoring of stimulated cycles in fertility treatment involving in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection
(ICSI)
Review question: can ultrasound alone be used safely without adding estradiol blood test measurements to monitor women undergoing
controlled ovarian hyperstimulation during IVF and ICSI? We reviewed the evidence on monitoring women undergoing controlled
ovarian hyperstimulation as part of IVF or ICSI by transvaginal ultrasound (TVUS) only versus traditional combined monitoring
(TVUS) and blood hormone (estradiol) levels.
Background: assisted reproduction techniques such as IVF and ICSI involve ovarian hyperstimulation. The ovaries are artificially
stimulated to produce follicles and then ovulation (release of a mature ovum or egg) is induced so that eggs can be retrieved for use in
either IVF or ICSI to produce embryos in the laboratory. Traditionally women undergoing controlled ovarian hyperstimulation prior
to ovulation induction have been monitored by TVUS and measurement of the hormone estradiol level in their blood. The aim of
monitoring is to detect the optimum time to induce ovulation (by the administration of human chorionic gonadotrophin or luteinising
hormone) and to determine an adequate response to ovarian hyperstimulation to allow egg retrieval, but importantly also to identify
women at risk of the potentially serious rare condition of ovarian hyperstimulation syndrome (OHSS). It has been suggested that a
simplified protocol of monitoring by TVUS alone may reduce unnecessary anxiety and operational costs during IVF and ICSI.
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Study characteristics: we included six randomised controlled trials conducted in the UK, France, Spain, Israel and the US, including
781 women. They compared monitoring with TVUS only versus TVUS plus serum estradiol concentration in women undergoing
ovarian hyperstimulation for IVF and ICSI treatment. The evidence was current to May 2014.
Key results: none of the six studies reported our primary outcome of live birth rate. Pooled data showed no evidence of a difference
in clinical pregnancy rate between monitoring with TVUS only and monitoring with TVUS plus estradiol measurement (odds ratio
(OR) 1.10; 95% CI 0.79 to 1.54; four studies; N = 617; I² = 5%; low quality evidence). Our findings suggest that compared with
women with a 34% chance of clinical pregnancy using monitoring with TVUS plus serum estradiol, the clinical pregnancy rate in
women using TVUS only was between 29% and 44%. There was no evidence of a difference in OHSS between the two arms (OR
1.03; 95% CI 0.48 to 2.20; six studies; N = 781; I² = 0%; low quality evidence), suggesting that compared with women with a 4%
chance of OHSS using monitoring with TVUS plus serum estradiol, the OHSS rate in women monitored by TVUS only was between
2% and 8%.
Quality of the evidence: the evidence was of low quality. Limitations included imprecision and potential bias due to unclear randomisa-
tion methods, allocation concealment and blinding, as well as differences in the treatment protocols. Quality assessment was hampered
by a lack of methodological descriptions in several studies. Two studies reported funding by pharmaceutical companies, whereas the
remaining four studies did not report their sources of funding.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only compared to monitoring with TVUS plus serum estradiol for women undergoing ovarian stimulation with
gonadotrophins in IVF and ICSI procedures
Population: Women undergoing ovarian stimulation with gonadotrophins in IVF and ICSI procedures
Settings: Hospital or outpatient assisted reproduction units
Intervention: Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only
Comparison: Monitoring with TVUS plus serum estradiol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Monitoring with TVUS
plus serum estradiol
Monitoring by TVUS only
Live birth per woman No evidence available, as none of the included studies reported live birth as an outcome
Clinical pregnancy per
woman
337 per 1000 361 per 1000
(287 to 439)
OR 1.05
(0.79 to 1.54)
617
(4 studies)
⊕⊕©©
low1,6
No difference demon-
strated between monitor-
ing by TVUS only and
TVUS plus serum estra-
diol
Mean number of oocytes
retrieved per woman
The mean number of oocytes retrieved per woman in
the intervention groups was
0.32 higher (0.6 lower to 1.24 higher)
595
(5 studies)
⊕⊕©©
low2,7
No difference demon-
strated between monitor-
ing by TVUS only and
TVUS plus serum estra-
diol
Cycle cancellation rate
per woman
36 per 1000 17 per 1000
(3 to 140)
OR 0.57
(0.07 to 4.39)
115
(2 studies)
⊕⊕©©
low3,6
No difference demon-
strated between monitor-
ing by TVUS only and
TVUS plus serum estra-
diol
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OHSS rate (mild, mod-
erate or severe) per
woman
36 per 1000 36 per 1000
(18 to 75)
OR 1.03
(0.48 to 2.20)
781
(6 studies)
⊕⊕©©
low4,5,6
No difference demon-
strated between monitor-
ing by TVUS only and
TVUS plus serum estra-
diol
Two studies reported no
incidence of OHSS
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Methods of allocation concealment inadequately described in the four trials; none of the trials adequately described blinding
2 Inadequate description of methods of randomisation in two of the five trials, allocation concealment all of the five trials and blinding in
four of the five trials
3 Methods of randomisation and allocation concealment inadequately described in one of the two trials
4 Methods of randomisation inadequately described in three of the six trials, allocation concealment inadequately described in all the six
trials and blinding inadequately described in five of the six trials
5 No definition of OHSS provided by authors of these 6 studies
6 Serious imprecision with wide confidence intervals
7 Unclear whether mean values correctly calculated (i.e. whether they include zero counts for cancelled cycles)
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B A C K G R O U N D
The overall aim of in vitro fertilisation (IVF) and intra-cytoplas-
mic sperm injection (ICSI) in assisted reproduction is to achieve
pregnancy and ultimately live births. A successful outcome from
IVF and ICSI is dependent upon a preliminary phase of con-
trolled ovarian hyperstimulation (COH) using exogenous go-
nadotrophins. The aim of COH is to produce multiple follicles
and thereafter to induce follicle maturation. Ovulation is then
induced by administration of human chorionic gonadotrophin
(hCG) or luteinizing hormone, which then allows optimal and
multiple opportunities for subsequent fertilisation. However, dur-
ing this process of COHand induction there exists the risk of ovar-
ian hyperstimulation syndrome (OHSS), which is the most seri-
ous iatrogenic complication of ovarian stimulation. There is de-
bate over whether women should be monitored during COH us-
ing a combination of transvaginal ultrasound (TVUS) and serum
estradiol measurements or by TVUS alone.
Description of the condition
The aim of achieving clinical pregnancy and ultimately live births
must be balanced with the risks associated with assisted repro-
ductive techniques, and specifically those related to ovarian hy-
perstimulation. OHSS is a systemic condition associated with de-
velopment of a large number of follicles and is a potentially fatal
condition (Delvigne 2002; Jenkins 2006; Schenker 1978). OHSS
can lead to ascites, pleural and pericardial effusion, haemoconcen-
tration, venous thromboembolism, hepatorenal failure and coag-
ulopathy (Borase 2012; Delvigne 2002; Jenkins 2006; Schenker
1978). It has been suggested that the condition is related to the
release of vasoactive chemicals from the ovaries during COH and
ovulation induction, which leads to increased vascular permeabil-
ity and thus fluid shifts extravascularly (Jenkins 2006). However,
the exact aetiology remains unknown. The incidence of OHSS is
estimated to range from 0.2% to 2.7% of all assisted reproductive
cycles, including intra-uterine insemination (Asch 1991; Ferraretti
2012;MacDougall 1992; Nygren 2002; Roest 1996; Smitz 1990).
Description of the intervention
COH is monitored by means of TVUS in order to gain informa-
tion on the number and size of developing follicles and to deter-
mine the optimal time for hCG administration prior to oocyte
retrieval. Some fertility units measure serum estradiol concentra-
tion alongside TVUS during the course of COH to provide added
information about the ovarian response and the potential risk of
hyperstimulation. Combined monitoring with TVUS and serum
estradiol concentrations has been suggested to be the gold stan-
dard for monitoring stimulated cycles in IVF and ICSI procedures
(Rizk 1992).
How the intervention might work
The number and size of follicles visualised at TVUS provide an
estimate of ovarian response and hCG is used to trigger ovulation
when a certain number of follicles reach a certain size. Estradiol,
which is produced by developing follicles, provides additional in-
formation which is believed to further improve the decision mak-
ing process; follicle maturity is supported by adequate estradiol
levels while there is an increased risk of OHSS in the presence of
very high levels. The overall aim is to ensure optimal stimulation
of the ovaries and to reduce the incidence and severity of OHSS
whilst obtaining a successful treatment outcome.
TVUS monitoring alone has been reported to provide more ac-
curate information on follicular number and size than can be ob-
tained by serum estradiol concentration alone in women with
anovulatory infertility undergoing gonadotrophin induction ther-
apy (Haning 1982; Hardiman 1990; Shoham 1991).
A cohort study comparing TVUS only versus TVUS plus hor-
monal determinations, including serum estradiol concentrations,
for ovarian monitoring in women undergoing IVF reported no
differences in live birth rate and the incidence of OHSS, and there
was a significant economic benefit in the TVUS only monitor-
ing protocol (Murad 1998). Another cohort study reported that
TVUS alone, performed during COH in IVF and intra-uterine
insemination, predicted 88% of cycle decisions as compared to
100% of cycle decisions that were predicted using combined mon-
itoring (Confino 1996).
One non-randomised study reported no differences in IVF out-
comes and incidence of OHSS between women whose ovarian
response was monitored by TVUS and serum estradiol concen-
tration on the day of human chorionic gonadotrophin (hCG) ad-
ministration and women who were monitored with TVUS only
and had the serum estradiol concentration checked if the risk of
OHSS was deemed to be high (Thomas 2002). A more recent
non-randomised study compared combined monitoring with ul-
trasound monitoring only in women undergoing IVF and ICSI
and reported equivalence in results between the two arms for the
primary outcome of number of mature oocytes at egg retrieval
(Vandekerckhove 2014).
Why it is important to do this review
The need for combined monitoring during COH in IVF and
ICSI is controversial. It has been suggested that close monitoring
is time consuming, expensive and inconvenient for the woman
(Howard 1988; Rainhorn 1987; Tan 1992). Simplification of IVF
therapy by minimal monitoring has been reported to have no
adverse effects on treatment outcome and the incidence of OHSS
(Abdalla 1989; Roest 1995; Tan 1994) and some IVF programs
have abandoned the use of the hormone assay completely (Kemeter
1989; Tan 1994; Vlaisavljevic 1992). This review is important
to couples, clinicians and researchers because if there is evidence
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that estradiol measurements are unnecessary, hospitals and clinics
could change their protocols thus reducing associated costs and
anxiety to the couple undergoing IVF or ICSI.
O B J E C T I V E S
To assess the effect of monitoring controlled ovarian hyperstimu-
lation (COH) in IVF and ICSI cycles in subfertile couples with
TVUS only versus TVUS plus serum estradiol concentration, with
respect to rates of live birth, pregnancy and OHSS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials only. Quasi-randomised trials were
excluded. Cross-over trials were excluded as they are an inappro-
priate design for this question because ‘success’ in the first phase
would prevent entry to subsequent phases of the study.
Types of participants
All women undergoing COH with gonadotrophins in IVF and
ICSI procedures.
Types of interventions
Monitoring by transvaginal ultrasound (TVUS) only versus com-
bined monitoring with TVUS plus serum estradiol concentra-
tions.
Types of outcome measures
Primary outcomes
Live birth rate per woman
Secondary outcomes
1. Pregnancy rate and multiple pregnancy rate per woman,
where clinical pregnancy is defined as a pregnancy diagnosed by
ultrasonographic visualisation of one or more gestational sacs or
definitive clinical signs of pregnancy. It includes ectopic
pregnancy. Multiple gestational sacs are counted as one clinical
pregnancy
2. Number of oocytes recovered per woman
3. Adverse outcomes: rate of ovarian hyperstimulation
syndrome (OHSS) per woman; number of cancelled cycles per
woman
4. Costs of monitoring with TVUS versus costs of monitoring
with TVUS plus serum estradiol concentrations
Search methods for identification of studies
Electronic searches
We searched the Menstrual Disorders and Subfertility Group
(MDSG) Specialised Register of controlled trials (Appendix 1)
(May 2014) without language restriction and in consultation with
the MDSG Trials Search Co-ordinator.
We conducted searches in the following electronic databases:
1. CENTRAL (Appendix 2) (April 2014);
2. MEDLINE (Appendix 3) (May 2014);
3. EMBASE (Appendix 4) (May 2014);
4. PsycINFO (Appendix 5) (May 2014);
5.CINAHL (Appendix 6) (May 2014).
Searching other resources
Two review authors (AW, AK) searched online research databases
without language or date restrictions (May 2014) including Clin-
icaltrials.gov, PubMed, LILACS/VHL, OpenGrey, ISI Web of
Knowledge, World Health Organization (WHO) Clinical Trial
Registries Platform and the Database of Abstracts of Reviews of
Effects (DARE) in The Cochrane Library. We handsearched on-
line relevant international and national peer-reviewed journals for
relevant studies. These included:
a) Human Reproduction;
b) Human Reproduction Update;
c) Molecular Human Reproduction (MHR);
d) Fertility and Sterility;
e) American Journal of Obstetrics and Gynecology;
f ) Best Practice & Research. Clinical Obstetrics &
Gynaecology;
g) Current Obstetrics and Gynaecology;
h) European Journal of Obstetrics, Gynecology, and
Reproductive Biology;
i) European Journal of Obstetrics and Gynecology;
j) Infertility and Reproductive Medicine Clinics of
North America;
k) International Journal of Gynaecology and
Obstetrics;
l) Journal of Reproductive Immunology;
m) Middle East Fertility Society Journal;
n) Obstetrics and Gynecology Clinics of North
America;
o) Placenta;
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p) Obstetrics, Gynaecology and Reproductive
Medicine;
q) Reproductive BioMedicine Online;
r) Reproductive Health Matters;
s) Sexual & Reproductive Healthcare;
t) Women’s Health Issues;
u) Women’s Health Medicine;
v) The Australian & New Zealand Journal of
Obstetrics & Gynaecology;
w) Reproduction, Fertility, and Development;
x) American Journal Reproductive Immunology
and Microbiology;
y) Biology of Reproduction;
z) Reproduction;
–) International Journal of Andrology.
In addition, we searched and checked reference lists of the included
studies, and contacted authors for clarification of study methodol-
ogy.We translated one article that was in French (Rongieres 2006)
and one in Spanish (Aguirre 2010).
Data collection and analysis
Selection of studies
Three review authors (IK, AW, AK) independently examined the
electronic search results for reports of possibly relevant trials. These
reports were retrieved in full. Three review authors independently
applied the selection criteria to the trial reports and resolved dis-
agreements by discussion with the other review author (SB). AK
and IK contacted authors for further clarification of study eligi-
bility and methods.
Data extraction and management
Data collection and analysis were conducted in accordance with
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Three review authors (IK, AW, AK) indepen-
dently extracted the data and information using a data extraction
form designed by the MDSG and pilot-tested by the authors. The
review authors were not blinded to the authors or publication jour-
nal when doing this. Results were compared and any differences
resolved by discussion. Where there was insufficient information
in the published report, AK and IK contacted the authors to re-
quest further information and clarification.
Assessment of risk of bias in included studies
Three authors (IK, AK, AW) independently assessed each trial for
risk of bias according to the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We assessed random se-
quence generation, allocation concealment, blinding, complete-
ness of outcome data (including use of intention-to-treat (ITT)
analysis) and selective outcome reporting for each trial. Other po-
tential sources of bias were also assessed. Each trial was categorised
as at low, unclear or high risk of bias for each domain based on
the standards described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Where the method was
not clearly reported, AK and IK contacted the authors for clarifi-
cation.
Measures of treatment effect
For dichotomous data we used the number of events in the con-
trol and intervention groups of each study to calculate Mantel-
Haenszel odds ratios (ORs). For continuous data we calculated the
mean difference (MD) between treatment groups. We presented
95% confidence intervals (CIs) for all outcomes.
Unit of analysis issues
The primary analyses were per woman randomised. For reported
data that did not allow valid analysis (for example ’per cycle’ rather
than ’per woman’, where the same women may contribute more
than one cycle) and when contact with authors yielded no addi-
tional data or when contacts were unsuccessful, we excluded the
outcomes from the analyses.
Dealing with missing data
We analysed the outcomes data of women as theywere randomised
by intention to treat (ITT). Trial authors were contacted for any
missing data. Where no additional information was forthcoming
and when we were not able to impute any missing values from
available data, we excluded these outcomes from the analyses.
Assessment of heterogeneity
We considered whether the clinical and methodological character-
istics of the included studieswere sufficiently similar formeta-anal-
ysis to provide a clinically meaningful summary. For each meta-
analysis, we assessed statistical heterogeneity using the I² and Chi²
statistics. Substantial heterogeneity was determined to be present
if I² was greater than 50%, or if P < 0.05 in the Chi² test for
heterogeneity (Higgins 2011).
Assessment of reporting biases
We planned that a funnel plot would be constructed if 10 or more
studies presented data on the same outcome.
Data synthesis
Where appropriate, we combined dichotomous data for meta-
analysis using the Mantel-Haenszel method to estimate pooled
ORs with 95% CIs using a fixed-effect model. For continuous
data, we computed weightedMD with 95% CI also using a fixed-
effect model in the meta-analysis.
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Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analysis to investigate hetero-
geneity, identified using the Chi² test (with P < 0.05 as evidence
of significant heterogeneity) and the I² statistic (Higgins 2011),
stratified by risk of bias in study design, where participants or as-
sessors, or both, were blinded versus non-blinded, as well as by
clinical characteristics of study populations such as OHSS risks
categories and first IVF versus previously failed IVF attempts. We
would have conducted these analyses had there been sufficient data
available.
Sensitivity analysis
As no included study reported our primary outcome of live birth
rates per woman, we did not perform the planned sensitivity anal-
ysis to assess whether the findings were robust or whether the con-
clusions would have differed if eligibility was restricted to studies
without a high risk of bias.
Summary of findings table
We prepared a summary of findings table using GRADEpro soft-
ware. This table evaluated the overall quality of the body of ev-
idence for the primary review outcomes using GRADE criteria
(study limitations (that is risk of bias), consistency of effect, impre-
cision, indirectness and publication bias). Judgements about evi-
dence quality (high, moderate or low) were justified, documented,
and incorporated into reporting of results for each outcome. See
Summary of findings for the main comparison.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
In the original review, our search strategy identified 1119 poten-
tially eligible reports of which two (Golan 1994; Lass 2003) met
our inclusion criteria. They involved 411 women who underwent
COH monitoring. One study (Murad 1998) was excluded as it
was not a randomised controlled trial (RCT).
In the 2014 review update, an additional four studies (Aguirre
2010; Rongieres 2006; Strawn 2007; Wiser 2012) involving 370
women were identified. One of these included studies (Strawn
2007) was reported as a conference abstract. Three studies were
excluded: onewas a quasi-randomised study (Schindler 2001); one
was not a randomised study (Kably Ambe 1994); and the other
was an RCT that compared combined monitoring with conven-
tional two-dimensional (2D) and three-dimensional (3D) ultra-
sound instruments (Raine-Fenning 2010). See Figure 1 for details
of the screening and selection process.
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Figure 1. Study flow diagram.
Included studies
A total of six studies was included in this review (see Characteristics
of included studies).
Study design and setting
The six included studies were all RCTs published between 1994
and 2012 (Aguirre 2010;Golan 1994; Lass 2003; Rongieres 2006;
Strawn 2007; Wiser 2012) and conducted in UK (N = 1), France
(N = 1), Spain (N = 1), Israel (N = 2) and the US (N = 1). One was
a multi-centre study involving four assisted conception units (Lass
2003). None of the trials specifically reported that the participants
included egg donors. We did not identify any cross-over trials.
Participants
The studies included 781 women (sample size ranged from 50
to 297), 394 in the control groups and 387 in the intervention
groups, with an overall age range between 23 and 42 years. Two
studies included only women admitted for the first IVF attempt
(Golan 1994; Wiser 2012) and two studies included women who
had had less than three previous unsuccessful IVF cycles (Aguirre
2010; Lass 2003).Women for ICSI were excluded from one study
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(Lass 2003) and so were women with a previous history of seri-
ous OHSS (Rongieres 2006). Most participants were women with
subfertility problems due to tubal factors, endometriosis, polycys-
tic ovary syndrome (PCOS), male factors or unexplained infertil-
ity.
Interventions
In this review, ovarian monitoring in the intervention group was
conducted by TVUS only; and that of the control group by TVUS
plus serum estradiol concentration. All six studies reported the use
of TVUS to measure follicular growth. Details of COH protocols
were not available for every study, and they differed in the use of
agonist or antagonist gonadotrophin releasing hormone (GnRH),
human menopausal gonadotrophin (hMG) or recombinant folli-
cle stimulating hormone (rFSH). Three studies based the protocol
used and dose according to individual response (Golan 1994) or
as preferred or determined by the clinicians (Strawn 2007; Wiser
2012). In one study, all women had hormonal assays and ultra-
sound examinations but the results were only made known to the
clinicians after oocyte retrieval (Golan 1994).
Outcomes
Primary outcomes: none of the six included studies reported the
primary outcome of live birth rate. One study reported the ongo-
ing pregnancy rate per cycle initiated (Strawn 2007).
Secondary outcomes: four studies reported the outcome clinical
pregnancy rate per woman (Aguirre 2010; Lass 2003; Rongieres
2006; Wiser 2012). Two studies reported pregnancy rate per
oocyte retrieval (Golan 1994; Strawn 2007) and they were ex-
cluded from our analysis as no further details were provided when
the authors were contacted. Five studies reported the number of
oocytes retrieved per woman (Aguirre 2010; Golan 1994; Lass
2003; Strawn 2007;Wiser 2012). Three studies reported the num-
ber of cycle cancellations: due to OHSS (Strawn 2007), insuffi-
cient treatment response (Wiser 2012), and one study reported
that cycle cancellation was similar in both arms but no data were
presented (Rongieres 2006). One study presented the likely costs
which might be saved by avoiding serum hormone determina-
tion (Golan 1994). All six studies reported the number of cases of
OHSS.
Excluded studies
We excluded three studies. One was a quasi-randomised study
(Schindler 2001); one was not a randomised study (Kably Ambe
1994); and one RCT (Raine-Fenning 2010) compared com-
bined monitoring with 3D ultrasound (US) versus 2D US (see
Characteristics of excluded studies).
Risk of bias in included studies
See Risk of bias in included studies; Figure 2; Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three studies were at low risk of selection bias related to ran-
dom sequence generation as they used computer randomisation
(Aguirre 2010; Lass 2003;Wiser 2012). In one study women were
randomised by ’drawing of lots’ (Rongieres 2006) and the meth-
ods of randomisation were not described in two studies (Golan
1994; Strawn 2007). These three studies were considered to be at
an unclear risk of bias.
For allocation concealment, two studies used sealed envelopes (
Wiser 2012) with unique identification (ID) (Lass 2003) but did
not give details whether the sealed envelopes were consecutively
numbered and opaque, so they were rated as at unclear risk of bias.
Four studies did not describe allocation concealment and were
therefore at unclear risk of this bias (Aguirre 2010; Golan 1994;
Rongieres 2006; Strawn 2007). The authors were contacted but
they were either not able to provide these methodological details
or did not respond to our enquiry.
Blinding
For the women participating in the studies, we did not consider
that blinding was likely to influence the risk of performance bias
for the IVF outcomes assessed. However, there was potential for
performance and detection bias in the outcomes of fertilisation
and subsequent clinical pregnancy when the operators were not
blinded to the allocation. One study reported that patients were
blinded for the allocation (Lass 2003) but did not describe the
method. The other three studies did not report methods of patient
blinding (Aguirre 2010; Golan 1994; Wiser 2012).
In one study, women in the intervention and control groups re-
ceived combined monitoring and results of estradiol levels were
only made known to the clinicians after oocyte retrieval (Golan
1994).
Incomplete outcome data
Analysis of outcomes based on the ITT principle was conducted in
one study (Golan 1994) where data were analysed as participants
were randomised. Nine women had their treatment discontinued
due to risk of OHSS: five from the TVUS group and three from
the combined group (Lass 2003). Four womenwere excluded from
the study due to non-adherence to the protocol (Aguirre 2010),
and one women in the TVUS group was excluded due to insuffi-
cient response to treatment (Wiser 2012). There was no report of
attrition in one study (Rongieres 2006).
For the reporting of number of oocytes retrieved per woman, it was
not clear from the included studies that the means for the number
of oocytes were reported correctly, that is including zero counts
for those women with cancelled cycles, as none of the included
studies provided this information.
Selective reporting
All six studies reported outcomes pre-specified in themethods sec-
tion. One study reported comparable cycle cancellation rates and
mean numbers of oocytes retrieved between the two arms but no
data were presented (Rongieres 2006). Some outcomes were not
of interest in this review, such as fertilisation rate, implantation
rate, miscarriage rate, ectopic pregnancy rate, number of embryos
transferred, duration of hMG treatment, number of hMG am-
poules used and endometrial thickness, and these data were nei-
ther extracted nor analysed.
Other potential sources of bias
Use of a prospective power calculation was not reported in five
studies (Aguirre 2010;Golan 1994; Rongieres 2006; Strawn 2007;
Wiser 2012).
Defintions of clinical pregnancy were reported in three studies
(Lass 2003; Rongieres 2006; Wiser 2012) but none of the six
studies provided a definition of OHSS or clarified whether the
number of oocytes retrieved per woman was calculated to include
zero count.
Another potential source of bias, imbalance in baseline character-
istics, was deemed at low risk in four included studies (Aguirre
2010;Golan 1994; Lass 2003;Wiser 2012) which reported similar
baseline characteristics in relation to age, body mass index (BMI)
and causes of infertility between the intervention and the control
groups. Any baseline imbalance could be considered as a possible
indicator of allocation bias. Two studies provided demographic
details which were comparable between the two arms but there
was no information on the causes of infertility (Rongieres 2006;
Strawn 2007).
Ovarian stimulation protocols differed between the two arms in
three studies: according to the individual’s response (Golan 1994)
and the physician’s preference (Strawn 2007; Wiser 2012).
Effects of interventions
See: Summary of findings for the main comparisonMonitoring
ovarian stimulation by transvaginal ultrasound (TVUS) only
compared to monitoring with TVUS plus serum estradiol for
women undergoing ovarian stimulation with gonadotrophins in
IVF and ICSI procedures
See Summary of findings for the main comparison.
Transvaginal ultrasound (TVUS) only versus TVUS
plus serum estradiol concentrations
Primary outcome
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Live birth rate
• None of the six included studies reported our primary
outcome of live birth rate.
Secondary outcomes
1. Pregnancy rate
There was no evidence of a difference between ovarian monitoring
with TVUS only and ovarian monitoring with TVUS plus estra-
diol measurement on the clinical pregnancy rate per woman. This
outcome was reported in four studies (19/35 versus 14/35, 46/
148 versus 49/149, 26/88 versus 30/97, and 19/34 versus 12/31,
respectively; OR 1.10; 95% CI 0.79 to 1.54; N = 617; I² = 5%;
low quality evidence) (Analysis 1.1, Figure 4) (Aguirre 2010; Lass
2003; Rongieres 2006; Wiser 2012). This suggested that com-
pared with women with a 34% chance of clinical pregnancy using
monitoring with TVUS plus serum estradiol, the clinical preg-
nancy rate in women using TVUS only was between 29% and
44%.Two studiesmeasured the pregnancy rate per oocyte retrieval
only and so were excluded from the analysis (Golan 1994; Strawn
2007).
Figure 4. Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.1
Clinical pregnancy per woman.
2. Number of oocytes recovered per woman
There was no evidence of a difference in the mean number of
oocytes retrieved between the two arms in the five studies (MD
9.9 (SD 3.1) versus 10.9 (SD 4.2), 13.4 (SD 7.5) versus 11.7 (SD
8.4), 11.7 (SD 5.9) versus 11.4 (SD 6.1), 11 (SD 7.0) versus 9
(SD 4.0), and 11.7 (SD 8.0) versus 10.0 (SD 5.5), respectively;
MD 0.32; 95% CI -0.60 to 1.24; N = 596; I² = 17%; low quality
evidence) (Analysis 1.2, Figure 5) (Aguirre 2010; Golan 1994;
Lass 2003; Strawn 2007; Wiser 2012).
Figure 5. Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.2 Mean
number of oocytes retrieved per woman.
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One study reported a non-significant difference in the number of
oocytes retrieved but no data were presented (Rongieres 2006).
3. Adverse outcomes
3.1 Rate of ovarian hyperstimulation syndrome (OHSS),
including severe OHSS
No incidence of OHSSwas reported in two studies (Aguirre 2010;
Wiser 2012). Combining the results of six studies, we found no
difference in the total cases of OHSS between the two arms (0/35
versus 0/35, 0/34 versus 0/31, 1/25 versus 1/25, 4/57 versus 3/57,
7/148 versus 5/149, and 2/88 versus 5/97, respectively; OR 1.03;
95% CI 0.48 to 2.20; six studies; N = 781; I² = 0%; low quality
evidence) (Analysis 1.3, Figure 6) (Aguirre 2010; Golan 1994;
Lass 2003; Rongieres 2006; Strawn 2007;Wiser 2012), suggesting
that compared with women with a 4% chance of OHSS using
monitoring with TVUS plus serum estradiol, the OHSS rate in
women monitored by TVUS only was between 2% and 8%.
Figure 6. Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.3
OHSS rate (mild, moderate or severe) per woman.
Of the 28 cases of OHSS reported in all the six studies there were
four cases of severe OHSS, which showed no difference between
the two arms (1/57 versus 1/57 and 2/148 versus 0/149, respec-
tively) (Golan 1994; Lass 2003).
3.2 Number of cancelled cycles
Three studies reported this outcome. The cycle cancellation rate
was similar in the two arms of two studies (0/34 versus 1/31, 1/
25 versus 1/25; OR 0.57; 95% CI 0.07 to 4.39; N = 115; I² =
0%; low quality evidence) (Analysis 1.4, Figure 7) (Strawn 2007;
Wiser 2012). The third study reported comparable cancellation
rates between the two arms but no data were presented (Rongieres
2006).
Figure 7. Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.4 Cycle
cancellation rate per woman.
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4. Costs of monitoring with TVUS versus monitoring with
TVUS plus serum estradiol concentration
None of the six studies performed an economic analysis on the
cost-effectiveness of the two different types of ovarian monitoring.
However, one study (Golan 1994) suggested that US monitoring
could be highly cost-effective and avoiding serum hormone deter-
mination might save over USD 150 (1994 prices) in each cycle
and compensate for the cost of the GnRH analogue. No further
details were available from the studies or the authors.
D I S C U S S I O N
Summary of main results
There were no data on live births. With respect to pregnancy
outcomes, in pooling the data of these six trials involving 781
women we found no evidence that cycle monitoring by TVUS
alone was any less effective or efficacious than combined moni-
toring by TVUS plus estradiol assay. However, this interpretation
was limited by the imprecision of the findings and the overall low
quality of the included studies.
Overall completeness and applicability of
evidence
Although the pooled results of these six studies suggest that TVUS
alone may potentially be a satisfactory monitoring tool for women
undergoing COH for IVF or ICSI, the overall completeness and
applicability of the evidence is limited.
None of the studies reported our primary outcome of live births
and all of the studies were of low methodological quality. One
weakness was the variability of the inclusion criteria for partic-
ipants. The studies included women undergoing their first IVF
attempts (Golan 1994; Wiser 2012) as well as women who had
already received three previous IVF attempts (Aguirre 2010; Lass
2003). Women for both IVF and ICSI were included in one
study (Rongieres 2006) and women for ICSI were excluded in one
study (Lass 2003), as were women with previous serious OHSS
(Rongieres 2006). Women undergoing ICSI (that is those with
partners with male factor problems) may be younger than those
receiving IVF. These different patient selection criteria may have
led to bias in the results due to different responses to treatment. Ex-
cluding those with previous OHSS may lead to a spuriously lower
proportion of women with this condition in a subsequent cycle.
Women were enrolled for a single treatment cycle (Lass 2003), for
more than one cycle (Aguirre 2010; Rongieres 2006), and three
studies did not report the number of cycles (Golan 1994; Strawn
2007; Wiser 2012). The different inclusion criteria for women
participating in the studies included in this review limit its gener-
alisability.
Likewise, the criteria for stimulation protocols varied between the
studies and it is not clear how this difference would influence the
outcomes. In three studies all women were treated with a stan-
dardised protocol (Aguirre 2010; Golan 1994; Lass 2003) and in
two trials differing protocols were offered depending on clinical
assessment and physician preference (Strawn 2007; Wiser 2012).
One study described a standardised protocol with all women re-
ceiving GnRH analogues initially and with 35% to 36% of the
women receiving further GnRH antagonists depending on pre-
defined criteria of estradiol level or presence of one follicle ≥ 13
mm (Rongieres 2006). Furthermore, the timing of TVUS in cycles
varied between studies though the significance of this is uncertain
and likely reflects the individual local protocols.
There was a lack of definitions for the outcomes assessed. For the
three studies which presented the definitions of clinical pregnancy
(Lass 2003; Rongieres 2006; Wiser 2012) they differed, ranging
from ’fetal sac (with or without fetal heart activity) visualised by
US on day 28 to 42 after hCG’ (Lass 2003) to ’as confirmed by a
fetal heartbeat determined by TVUS; approximately 32 days after
embryo transfer’ (Wiser 2012) and ’presence of an intra-uterine
gestational sac at US’ (Rongieres 2006). The definition of OHSS
was not presented in any of the studies and it was uncertain if
the reported cases of ’severe’ OHSS in two studies (Golan 1994;
Lass 2003) were similar in nature. This lack of uniformity and
consistency in outcomes definitions is an important shortcoming
as there is potential for the assessed outcomes to be different, thus
affecting the generalisability and applicability of the evidence.
Some studies either did not report or were unable to provide in-
formation to allow computation of outcomes ’per woman’ when
’per cycle’ data only were reported. This resulted in two studies be-
ing excluded from the analysis for the outcome on pregnancy rate
(Golan 1994; Strawn 2007), further limiting the evidence base,
its generalisability and applicability. Our attempts to contact the
authors were unsuccessful and we received no response.
Cycle monitoring with both TVUS and estradiol measurement is
likely to involve higher costs (to cover technicians and laboratory
costs, outpatient attendance) when compared with TVUS alone.
Hormonal assays involve repeated venepuncture, which may cause
stress and anxiety to women. However, it is unclear if women
would bemore satisfied with combinedmonitoring and because of
a placebo effect with the perception that they are being monitored
more closely. In future research it would be useful to know which
monitoring protocol women were more satisfied with.
16Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI) (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Quality of the evidence
Using GRADE methods, the overall quality of the evidence was
rated as low for all comparisons (Summary of findings for themain
comparison). Themain reasons for downgrading the quality of the
evidence were risk of bias and imprecision. The methodological
quality of the included studies was poor. This was largely due to
some studies failing to describe their methods in adequate detail,
such asmethods of randomisation and allocation concealment and
patient characteristics, resulting in the small quantity of relevant
usable data that was available. In addition, five of the six studies did
not conduct data analyses based on the ITT principle. Our efforts
to contact study authors for further informationwere unsuccessful.
The addition of new trials in this update enables the aggregation
of outcomes data, especially for pregnancy rate per woman. The
methodological quality of the trials was variable (Figure 2, Figure
3). Population and treatment characteristics could influence the
success of the IVF treatment. It is difficult to determine whether or
not there was significant clinical heterogeneity as there was a lack of
methodological details, particularly in the pilot study presented as
a conference abstract (Strawn 2007). Overall, the included studies
appeared to investigate a shared research question with the same
intervention and comparator. Five of the six included studies took
place in assisted reproduction units (Aguirre 2010; Golan 1994;
Lass 2003; Rongieres 2006; Wiser 2012).
Blinding was variably reported in the studies. Women may feel
either anxious or reassured if they receive combined monitoring
and in this context an unblinded design would be potentially ben-
eficial to measure certain outcomes. However, women’s perception
of anxiety or reassurance from venepuncture for estradiol mea-
surement is unlikely to influence live birth and pregnancy rates.
Assessor blinding would reduce performance and detection bias
in oocyte retrieval and embryo transfer when they are not aware
of the women’s allocation status. In one study, women in the in-
tervention and control groups received combined monitoring and
results of the estradiol levels were made known to the clinicians
after oocyte retrieval (Golan 1994). Studies whereby women are
not blinded to their monitoring regime may be of clinical interest
in the future.
There was a possibility that some of the randomised women may
not have reached oocyte recovery stage due to cycles cancelled for
inappropriate COH (either an under or over response). This is
important in trials where ovarian response may be affected by the
monitoring regimen. In one study (Lass 2003) nine women left the
study before the hCG injection, six due to failure of human rFSH
treatment, one because of risk ofOHSS, one received saline instead
of hCG, and one woman failed to follow the drug protocol. In
this study a total of 42 women (14.1%) did not reach the embryo
transfer stage, although the reasons for discontinuing treatment
did not differ between the two groups.
For the reporting of number of oocytes retrieved per woman, it
was not clear from the included studies that the means reported
for oocytes correctly included zero counts for those with cancelled
cycles. This would have the effect of both increasing the mean and
reducing the standard deviation (SD), therefore exaggerating the
statistical significance of the comparisons. Lack of this information
from the studies and the authors increases the uncertainty of data
reliability. In addition, the interpretation of US may potentially
differ because it involves some degree of inter-observer variability,
especially in units where successive scans may be performed by
different personnel.
We contacted all authors for missing and additional informa-
tion about their studies but received no response. One author re-
sponded that the data were no longer available due to the long
time lapse from when the study was conducted, 20 years ago.
Potential biases in the review process
We did not exclude studies on the grounds of language and in-
cluded one Spanish and one French study. One study was a con-
ference abstract. Despite our efforts to contact authors, we were
unable to obtain further information from them and some bias in
the review process could have arisen due to the inclusion of trials
with insufficient information on methods and outcome data and
where authors did not respond to our enquiries.
Agreements and disagreements with other
studies or reviews
A recent systematic review of six studies reported that, compared
to TVUS plus hormonal measurement, monitoring COH with
TVUS only was unlikely to substantially change the chance of
achieving clinical pregnancy outcomes in women undergoing IVF
treatment (Martins 2013). They included five studies, all of which
were included in this review except for one (Strawn 2007).
One RCT that compared combined monitoring with traditional
two-dimensional (2D) US versus automated three-dimensional
(3D) US reported comparable outcomes for clinical pregnancy,
number of oocytes retrieved and number of fertilised oocytes
(Raine-Fenning 2010). This suggests that traditional 2D US is no
more or less efficient than 3D ultrasound for monitoring stimu-
lated cycles in assisted reproduction.
A recent study to validate the saliva-based estradiol assay for in-
tra- and inter-assay variability found that it was associated with
improved patient satisfaction and reduced anxiety (Zimon 2013),
and this method may provide an equivalent but ’patient-friendly’
alternative to serum-based assessment. However, in the absence
of any effectiveness and cost-effectiveness data from RCTs com-
paring the effects of serum estradiol and saliva-based estradiol as-
says, the non-invasive saliva-based estradiol assay would still incur
anxiety and costs. Serum estradiol may be perceived as a more
reliable parameter, especially in women at risk of OHSS in whom
decisions on cycle cancellation or elective freezing of oocytes or
embryos may need to be taken. However, as the findings of this
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review show that current evidence is limited, high quality RCTs to
assess monitoring methods would be welcome. A cyclemonitoring
protocol including both US and serum estradiol concentrations
may need to be retained as precautionary good clinical practice
and in a subset of women as a confirmatory test to identify those
at high risk of OHSS, such as women with a history of OHSS
or with polycystic ovaries, those exposed to ovulation induction,
and younger women undergoing assisted reproduction techniques
(Jenkins 2006).
No formal cost analysis was reported in these studies. The studies
reviewed were not designed to test the cost-effectiveness of the
two interventions. However, it was suggested that avoiding serum
hormone determination might save over USD 150 (at early 1990
prices) in each cycle and this would compensate for the cost of the
GnRHa (Golan 1994).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This reviewupdate foundno evidence from randomised controlled
trials to suggest that combined monitoring by TVUS and serum
estradiol ismore efficacious thanmonitoring byTVUS alone, with
regard to clinical pregnancy rates and the incidence of OHSS. The
number of oocytes retrieved appeared similar for both monitoring
protocols. The data suggest that both of thesemonitoringmethods
are safe and reliable. However, these results should be interpreted
with caution because the overall quality of the evidence was low.
Results were compromised by imprecision and poor reporting of
study methodology. A combined monitoring protocol including
both TVUS and serum estradiol may need to be retained as pre-
cautionary good clinical practice and as a confirmatory test in a
subset of women to identify those at high risk of OHSS.
Implications for research
To find a difference in an important but rare outcome such as
OHSS, a large randomised controlled study requiring the re-
cruitment of approximately 5000 women is needed for each ran-
domised arm, and this would pose a great methodological chal-
lenge. Based on the quoted risk of OHSS following IVF in Europe
of 1% (Ferraretti 2012) and a hypothetical trial of an intervention
for reduction of OHSS with a clinically meaningful effect size,
meaning to halve this risk (from 1% to 0.5%) with 90% power
and 95% confidence (alpha = 0.05), the trial would need 4675
women in each randomised arm. However, an economic evalua-
tion of the costs involved in these two monitoring methods and
assessing the views of the women undergoing cycle monitoring
would be welcome.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aguirre 2010
Methods Randomisation: randomisation list
Allocation concealment: not reported
Blinding of participants/investigators: no
Blinding of assessors: not reported
Number randomised: 70
Number analysed: 66
Intention-to-treat analysis: no
Power and sample calculation not reported
Duration of study: conducted from January 2006 to June 2007
Participants Women undergoing IVF, between 25 to 36 years of age with normal follicular reserve,
BMI and with less than 3 previous IVF cycles
Mean age: 32-33 years
Cause of infertility: female factors, male factors, mixed factors, unexplained
Similar demographic and infertility characteristics at baseline (age, BMI, basal FSH and
causes of infertility)
Interventions 1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determina-
tion (n=31)
2. Intervention: monitoring of ovarian induction by TVUS only (n=35)
Ovarian stimulation protocol: GnRH agonist, triptorelin, followed by rFSH
Outcomes 1. Primary: live birth rate not reported
2. Secondary: clinical pregnancy rate/woman, multiple pregnancy rate/woman, number
of oocytes retrieved/woman, number of cases of OHSS
Other outcomes reported: ICSI; fertilisation rate, implantation rate, miscarriage rate,
ectopic pregnancy rate, number of embryos transferred
Notes Country: Spain
Single centre
Unidad de Reproduccion Asistida Clinica Montpellier, Espana
Funding: Schering Plough
Definition of pregnancy not documented
Definition of OHSS not reported
Four women excluded due to non-adherence to treatment protocol
Number of cycles: 42 cycles for control group; 48 cycles for intervention group
Paper in Spanish
Author contacted: no response and no data details were available
Risk of bias
Bias Authors’ judgement Support for judgement
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Aguirre 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation list, no details given
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of participants and assessors not
reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Four women excluded due to non-adher-
ence to treatment protocol
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Low risk Comparable demographic and infertility
characteristics at baseline
Golan 1994
Methods Randomisation: methods unclear
Allocation concealment: methods unclear
Blinding of participants/investigators: patients not blind
Blinding of assessors: yes
Number randomised: 114
Number analysed: 114
Intention-to-treat analysis: yes
Power and sample calculation not reported
Duration of study: not stated
Participants Women admitted for first IVF attempts
Mean age: 30-31 years
Cause of infertility: tubal disease, male factor, endometriosis, unexplained
Similar demographic and infertility characteristics at baseline (age, mean duration of
infertility, and indications for IVF treatment)
Interventions 1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determina-
tion (n=57)
2. Intervention: monitoring of ovarian induction by TVUS only (n=57)
Ovarian stimulation protocol: human menopausal gonadotrophin (hMG), adjusting
dose according to individual response
Outcomes 1. Primary: live birth rate not reported
2. Secondary: pregnancy rate/oocyte retrieval, number of oocytes retrieved/woman, num-
ber of cases of OHSS, costs saved
Other outcomes reported: duration of hMG treatment, number of hMG ampoules used,
serum estradiol, embryos achieved, number of embryo replaced
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Golan 1994 (Continued)
Notes Country: Israel
Single centre
Assaf Harofeh Medical Centre, affiliated to Sackler Faculty of Medicine, Tel Aviv Uni-
versity, Israel
Funding: not stated
Definition of pregnancy not documented
Definition of OHSS not reported
Number of cycles not reported
Author contacted: responded that no further data details were available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly divided into 2
groups, no details given
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Both control and intervention groups re-
ceived ultrasonography and serumestradiol
measurement, the results were only made
known to the clinicians following oocyte
retrieval
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised included in analysis
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Low risk Comparable demographic and infertility
characteristics at baseline
Lass 2003
Methods Randomisation: computer-generated randomisation
Allocation concealment: individual sealed envelopes with unique identification
Blinding of participants/investigators: patient-blind
Blinding of assessors: no
Number randomised: 297
Number analysed: 288
Intention-to-treat analysis: no
Power and sample calculation described
Duration of study: one cycle only
Participants Women undergoing IVF treatment who had no more than 3 previous unsuccessful
attempts; women with PCOS were included; ICSI excluded
Mean age: 23-39 years
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Lass 2003 (Continued)
Cause of infertility: not reported
Similar demographic and infertility characteristics at baseline (age, BMI, duration of
infertility and no. of previous ART treatments)
Interventions 1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determina-
tion (n=148)
2. Intervention: monitoring of ovarian induction by TVUS only (n=149)
Ovarian stimulation protocol: pituitary down-regulation achieved by daily injection of
buserelin; recombinant human FSH dose according to clinical practice
Outcomes 1. Primary: livebirth rate not reported
2. Secondary: clinical pregnancy rate/woman, number of oocytes retrieved/woman, num-
ber of cases of OHSS
Other outcomes reported: dose of Gonal-F, endometrial thickness, number of follicles,
number of embryos transferred
Notes Country: UK
Multi-centres: 4 assisted conception units
Bourn Hall Clinic, Cambridge, UK
Funding: author worked for Serono
Definition of pregnancy: ’a pregnancy in which a fetal sac (with or without fetal heart
activity) was visualized by ultrasound on day 28-42 after hCG administration.’
Definition of OHSS: not reported
Nine women had their treatment discontinued due to the risk of OHSS, three from the
estradiol plus ultrasound group and five from the ultrasound-only group
A total of 42 women (14.1%) did not reach the embryo transfer stage, 19 in control
group and 23 in intervention group, reasons for discontinuing treatment did not differ
between the two groups
One cycle only
Author contacted: no response and no data details were available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Unclear risk Randomisation code for each patient pro-
vided in Individual sealed envelopes with
unique ID
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants blind
Blinding of assessors not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A total of 9 women (3%) did not complete
study
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Lass 2003 (Continued)
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk Causes of infertility not reported
Rongieres 2006
Methods Randomisation: by ’drawing of lots’
Allocation concealment: methods unclear
Blinding of participants/investigators: not reported
Blinding of assessors: not reported
Number randomised: 185
Number analysed: 185
Intention-to-treat analysis: yes
Power and sample calculation: not described
Duration of study: not reported
Participants Women undergoing IVF and ICST treatment; women with previous serious OHSS
excluded
Mean age: 24-42 years
Cause of infertility: not reported
Similar demographic at baseline (age, BMI, techniques (IVF, ICSI, TESSA))
Interventions 1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determina-
tion (n=97)
2. Intervention: monitoring of ovarian induction by TVUS only (n=88)
Ovarian stimulation protocol: GnRH agonist long protocol. 35% to 36% of the women
also received GnRH antagonists depending on predefined criteria of estradiol level or
presence of one follicle ≥ 13 mm
Outcomes 1. Primary: live birth rate not reported
2. Secondary: clinical pregnancy rate/woman, number of oocytes retrieved/woman, rate
of cycle cancellation/woman, number of cases of OHSS
Other outcomes reported: units of GnRH used, fertilisation rate
Notes Country: France
Single centre
Centre d’Assistance Médicale à la Procréation, Centre Hospitalier Universitaire, Stras-
bourg
Funding: not reported
Definition of pregnancy: ’presence of an intra-uterine gestational sac at US’
Definition of OHSS: not stated
Number of cycles: 1.8±1.2 (control), 1.2±1.4 (intervention)
Author contacted: no response and data details were available
Risk of bias
Bias Authors’ judgement Support for judgement
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Rongieres 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk ’Drawing of lots’, no details
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of participants and assessors not
reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised included in analysis
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Unclear risk Causes of infertility not reported
Strawn 2007
Methods Randomisation: methods unclear
Allocation concealment: methods unclear
Blinding of participants/investigators: not reported
Blinding of assessors: not reported
Number randomised: 50
Number analysed: 49
Intention-to-treat analysis: no
Power and sample calculation not described
Duration of study: not reported
Participants Women undergoing IVF treatment
Mean age: 32 years
Cause of infertility: not reported
Similar demographic characteristics at baseline (weight and BMI)
Interventions 1. Control: monitoring of ovarian induction by TVUS plus estradiol assay (n=25)
2. Intervention: monitoring of ovarian induction by TVUS only (n=24)
Ovarian stimulation protocol: based on practitioner preference, no details given
Outcomes 1. Primary: live birth rate not reported
2. Secondary: ongoing pregnancy rate/cycle, number of oocytes retrieved/woman, cycle
cancellation rate/woman, number of cases of OHSS
Other outcomes reported: number of units of hMG used, level of estradiol, number of
embryos transferred
Notes Country: US
Funding: Azko-Nobel Pharamceutical corporation
Definition of pregnancy: not reported
Number of cycles: not reported
One cycle was cancelled in the TVUS arm and one cycle cancelled in the estradiol plus
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Strawn 2007 (Continued)
TVUS arm
Author contacted: no response and no data details were available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods unclear
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of participants and assessors not
reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk one cycle was cancelled in the TVUS arm
and one cycle cancelled in the estradiol plus
TVUS arm
Selective reporting (reporting bias) Unclear risk Not clear
Other bias Unclear risk Causes of infertility not reported; stimula-
tion protocol based on practitioner prefer-
ence
Wiser 2012
Methods Randomisation: computer-generated
Allocation concealment: sealed envelopes
Blinding of participants/investigators: not reported
Blinding of assessors: not reported
Number randomised: 65
Number analysed: 63
Intention-to-treat analysis: no
Power and sample calculation not reported
Duration of study: conducted from 2007 to 2009
Participants Women undergoing first IVF attempts, younger than age 40 years
Mean age: 31-32 years
Cause of infertility: male factor, PCOS, endometriosis, mechanical, unexplained
Similar demographic and infertility characteristics at baseline (age, BMI, basal FSH,
causes of infertility and ovarian reserve)
Interventions 1. Control: monitoring of ovarian induction by TVUS plus serum estradiol and proges-
terone determination (n=30)
2. Intervention: monitoring of ovarian induction by TVUS only (n=33)
Ovarian stimulation protocol: either long GnRH agonist protocol or antagonist protocol
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Wiser 2012 (Continued)
as determined by the physician
Outcomes 1. Primary: live birth rate not reported
2. Secondary: clinical pregnancy rate/woman, number of oocytes retrieved/woman; num-
ber of cases of OHSS
Other outcomes reported: number of induction days, number of gonadotrophin am-
poules used, endometrial thickness, estradiol levels, number of embryos transferred,
mean score of leading embryos transferred
Notes Country: Israel
Single centre
Meir Medical Center, Kfar Saba, affiliated to Sackler Faculty of Medicine, Tel Aviv
University, Israel
Funding: not stated (authors declared no conflict of interest)
Definition of clinical pregnancy: confirmed by ’by a fetal heartbeat determined by
transvaginal ultrasound approximately 32 days after embryo transfer.’
Definition of OHSS: not reported
One patient (in the control group) was cancelled due to insufficient response to treatment
Number of cycles not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Unclear risk Each patient chose a sealed envelope con-
taining the randomised assignment to ei-
ther the study or the control group
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of participants and assessors not
reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Twopatients excluded after randomisation:
one woman conceived spontaneously un-
der suppression with GnRH agonist and
one left the clinic before starting treatment
Onewoman (in the control group)was can-
celled due to insufficient response to treat-
ment, results did not reflect this
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk Comparable demographic and infertility
characteristics at baseline, stimulation pro-
tocols varied as determined by the physi-
cian
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TVUS - Transvaginal ultrasonography; OHSS - Ovarian hyperstimulation syndrome; ICSI - Intra-cytoplasmic sperm injection; TESE:
Testicular sperm extraction; hMG - Human menopausal gonadotrophin; hCG - Human chorionic gonadotrophin; GnRH - Go-
nadotropin-releasing hormone; FSH - Follicle stimulating hormone; PCOS - Polycystic ovary syndrome; BMI - body mass index
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kably Ambe 1994 This is a non-randomised trial
Raine-Fenning 2010 The intervention comprises estradiol measurement plus two-dimensional ultrasound versus estradiol mea-
surement plus SonoAVC (three-dimensional ultrasound) and does not satisfy the inclusion criteria of the
review
Schindler 2001 This is a quasi-randomised trial in which women were randomised by month of birth
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D A T A A N D A N A L Y S E S
Comparison 1. Ultrasound only versus ultrasound plus estradiol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical pregnancy per woman 4 617 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.79, 1.54]
2 Mean number of oocytes
retrieved per woman
5 596 Mean Difference (IV, Fixed, 95% CI) 0.32 [-0.60, 1.24]
3 OHSS rate (mild, moderate or
severe) per woman
6 781 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.48, 2.20]
4 Cycle cancellation rate per
woman
2 115 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.07, 4.39]
Analysis 1.1. Comparison 1 Ultrasound only versus ultrasound plus estradiol, Outcome 1 Clinical pregnancy
per woman.
Review: Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)
Comparison: 1 Ultrasound only versus ultrasound plus estradiol
Outcome: 1 Clinical pregnancy per woman
Study or subgroup Ultrasound only
Ultrasound
+ estradiol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lass 2003 46/148 49/149 51.2 % 0.92 [ 0.57, 1.50 ]
Rongieres 2006 26/88 30/97 30.6 % 0.94 [ 0.50, 1.76 ]
Aguirre 2010 19/35 14/35 9.7 % 1.78 [ 0.69, 4.60 ]
Wiser 2012 19/34 12/31 8.4 % 2.01 [ 0.75, 5.40 ]
Total (95% CI) 305 312 100.0 % 1.10 [ 0.79, 1.54 ]
Total events: 110 (Ultrasound only), 105 (Ultrasound + estradiol)
Heterogeneity: Chi2 = 3.17, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours US only Favours US + estradiol
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Analysis 1.2. Comparison 1 Ultrasound only versus ultrasound plus estradiol, Outcome 2 Mean number of
oocytes retrieved per woman.
Review: Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)
Comparison: 1 Ultrasound only versus ultrasound plus estradiol
Outcome: 2 Mean number of oocytes retrieved per woman
Study or subgroup Ultrasound only
Ultrasound
+ estradiol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Aguirre 2010 35 9.9 (3.1) 35 10.9 (4.2) 28.4 % -1.00 [ -2.73, 0.73 ]
Lass 2003 148 11.7 (5.9) 149 11.4 (6.1) 45.5 % 0.30 [ -1.06, 1.66 ]
Wiser 2012 34 11.7 (8) 31 10 (5.5) 7.7 % 1.70 [ -1.61, 5.01 ]
Golan 1994 57 13.4 (7.5) 57 11.7 (8.4) 9.9 % 1.70 [ -1.22, 4.62 ]
Strawn 2007 25 11 (7) 25 9 (4) 8.5 % 2.00 [ -1.16, 5.16 ]
Total (95% CI) 299 297 100.0 % 0.32 [ -0.60, 1.24 ]
Heterogeneity: Chi2 = 4.85, df = 4 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours US only Favours US + estradiol
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Analysis 1.3. Comparison 1 Ultrasound only versus ultrasound plus estradiol, Outcome 3 OHSS rate (mild,
moderate or severe) per woman.
Review: Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)
Comparison: 1 Ultrasound only versus ultrasound plus estradiol
Outcome: 3 OHSS rate (mild, moderate or severe) per woman
Study or subgroup Ultrasound only
Ultrasound
+ estradiol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wiser 2012 0/34 0/31 Not estimable
Aguirre 2010 0/35 0/35 Not estimable
Rongieres 2006 2/88 5/97 35.4 % 0.43 [ 0.08, 2.26 ]
Strawn 2007 1/25 1/25 7.3 % 1.00 [ 0.06, 16.93 ]
Golan 1994 4/57 3/57 21.2 % 1.36 [ 0.29, 6.36 ]
Lass 2003 7/148 5/149 36.1 % 1.43 [ 0.44, 4.61 ]
Total (95% CI) 387 394 100.0 % 1.03 [ 0.48, 2.20 ]
Total events: 14 (Ultrasound only), 14 (Ultrasound + estradiol)
Heterogeneity: Chi2 = 1.49, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours US only Favours US + estradiol
32Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI) (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Ultrasound only versus ultrasound plus estradiol, Outcome 4 Cycle cancellation
rate per woman.
Review: Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)
Comparison: 1 Ultrasound only versus ultrasound plus estradiol
Outcome: 4 Cycle cancellation rate per woman
Study or subgroup Ultrasound only
ultrasound
+ estradiol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wiser 2012 0/34 1/31 61.7 % 0.29 [ 0.01, 7.51 ]
Strawn 2007 1/25 1/25 38.3 % 1.00 [ 0.06, 16.93 ]
Total (95% CI) 59 56 100.0 % 0.57 [ 0.07, 4.39 ]
Total events: 1 (Ultrasound only), 2 (ultrasound + estradiol)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours US only Favours US + estradiol
A P P E N D I C E S
Appendix 1. Menstrual Disorders and Subfertility Group (MDSG) search strategy (20 May 2014)
Keywords CONTAINS “IVF”or “ICSI”or“in vitro fertilisation”or “in vitro fertilization”or “in-vitro fertilisation procedure”or“in-
vitro fertilisation techniques”or “intracytoplasmic sperm injection”or “Embryo”or “oocytes”or “ovarian hyperstimulation”or “ovarian
hyperstimulation syndrome”or“ovarian stimulation”or“ovarian response”or“ovarian stimulation syndrome”
AND
Keywords CONTAINS “ultrasonography” or “ultrasound” or“ultrasound guidance” or “ultrasound, pelvic” or “monitoring” or Title
CONTAINS “ultrasonography” or “ultrasound” or“ultrasound guidance” or “ultrasound, pelvic”or “monitoring”
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy (April
2014)
1 Ovulation Induction/ (981)
2 Ovarian Hyperstimulation Syndrome/ (140)
3 Ovarian Follicle/ (346)
4 Follicle Stimulating Hormone/ (1546)
5 Luteinizing Hormone/ (1451)
6 Gonadotropins/ (194)
7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (651)
8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (1225)
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9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (620)
10 gonadotrop?in$.tw. (2694)
11 (luteiniz$ adj5 hormone$).tw. (1225)
12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (2651)
13 or/1-12 (6658)
14 exp Fertilization in Vitro/ (1609)
15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (2758)
16 Intracytoplasmic Sperm Injections/ (394)
17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (516)
18 ICSI.tw. (801)
19 or/14-18 (3300)
20 13 and 19 (1492)
21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (10233)
22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (390)
23 exp Estradiol/ (3362)
24 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (437)
25 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (1520)
26 exp Ultrasonography/ (6733)
27 echograph$.tw. (160)
28 or/21-27 (19410)
29 20 and 28 (470)
30 limit 29 to yr=“2013 -Current” (10)
Appendix 3. Ovid MEDLINE search strategy (20 May 2014)
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 Ovulation Induction/ (8926)
2 Ovarian Hyperstimulation Syndrome/ (1736)
3 Ovarian Follicle/ (15163)
4 Follicle Stimulating Hormone/ (32964)
5 Luteinizing Hormone/ (42967)
6 Gonadotropins/ (8402)
7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (5299)
8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (16264)
9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (3965)
10 gonadotrop?in$.tw. (53846)
11 (luteiniz$ adj5 hormone$).tw. (25275)
12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (45955)
13 or/1-12 (145856)
14 exp Fertilization in Vitro/ (27947)
15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (24620)
16 Intracytoplasmic Sperm Injections/ (4600)
17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (5141)
18 ICSI.tw. (5486)
19 or/14-18 (36686)
20 13 and 19 (10815)
21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (216336)
22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (4931)
23 exp Estradiol/ (74460)
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24 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (3412)
25 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (12149)
26 exp Ultrasonography/ (247866)
27 echograph$.tw. (8633)
28 or/21-27 (470968)
29 20 and 28 (3305)
30 randomized controlled trial.pt. (373788)
31 controlled clinical trial.pt. (88373)
32 randomized.ab. (293663)
33 randomised.ab. (58854)
34 placebo.tw. (158182)
35 clinical trials as topic.sh. (169943)
36 randomly.ab. (212697)
37 trial.ti. (126393)
38 (crossover or cross-over or cross over).tw. (60653)
39 or/30-38 (943680)
40 exp animals/ not humans.sh. (3939073)
41 39 not 40 (870261)
42 29 and 41 (511)
43 (201310$ or 201311$ or 201312$).ed. (232178)
44 2014$.ed. (381204)
45 2014$.dp. (372749)
46 43 or 44 or 45 (913311)
47 42 and 46 (13)
Appendix 4. EMBASE search strategy (20 May 2014)
Database: Embase < 1980 to 2014 Week 20>
Search Strategy:
--------------------------------------------------------------------------------
1 Ovulation Induction/ (10545)
2 Ovarian Hyperstimulation Syndrome/ (6330)
3 Ovarian Follicle/ (13554)
4 Follicle Stimulating Hormone/ (40096)
5 Luteinizing Hormone/ (47094)
6 Gonadotropins/ (21901)
7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (6292)
8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (19113)
9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (5426)
10 gonadotrop?in$.tw. (54983)
11 (luteiniz$ adj5 hormone$).tw. (23538)
12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (47601)
13 or/1-12 (161565)
14 exp Fertilization in Vitro/ (38208)
15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (33773)
16 exp Intracytoplasmic Sperm Injection/ (12528)
17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (6555)
18 ICSI.tw. (9464)
19 or/14-18 (52926)
20 13 and 19 (16720)
21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (287310)
22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (5859)
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23 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (3683)
24 (hormon$ adj5 (measure$ or monitor$ or assay$)).tw. (16839)
25 exp ultrasound/ (101105)
26 exp echography/ (501808)
27 echograph$.tw. (10048)
28 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (13391)
29 or/21-28 (678508)
30 20 and 29 (3133)
31 Clinical Trial/ (830705)
32 Randomized Controlled Trial/ (341422)
33 exp randomization/ (61977)
34 Single Blind Procedure/ (18225)
35 Double Blind Procedure/ (113073)
36 Crossover Procedure/ (38825)
37 Placebo/ (238864)
38 Randomi?ed controlled trial$.tw. (97655)
39 Rct.tw. (13725)
40 random allocation.tw. (1297)
41 randomly allocated.tw. (20015)
42 allocated randomly.tw. (1916)
43 (allocated adj2 random).tw. (710)
44 Single blind$.tw. (14129)
45 Double blind$.tw. (139503)
46 ((treble or triple) adj blind$).tw. (361)
47 placebo$.tw. (195795)
48 prospective study/ (249423)
49 or/31-48 (1350956)
50 case study/ (25746)
51 case report.tw. (256378)
52 abstract report/ or letter/ (888025)
53 or/50-52 (1164600)
54 49 not 53 (1313533)
55 30 and 54 (645)
56 (201310$ or 201311$ or 201312$).em. (67090)
57 2014$.em. (694933)
58 2014$.dp. (41843)
59 56 or 57 or 58 (764192)
60 55 and 59 (20)
Appendix 5. PsycINFO search strategy (20 May 2014)
Database: PsycINFO <1806 to May Week 2 2014>
Search Strategy:
--------------------------------------------------------------------------------
1 exp Reproductive Technology/ or exp Ovulation/ or exp Infertility/ (2907)
2 (ovulat$ adj5 (induct$ or stimulat$)).tw. (50)
3 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (211)
4 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (9)
5 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (613)
6 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (37)
7 ICSI.tw. (44)
8 or/1-7 (3282)
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9 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (2679)
10 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (119)
11 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (159)
12 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (1100)
13 exp Ultrasound/ (983)
14 echograph$.tw. (50)
15 or/9-14 (4266)
16 8 and 15 (51)
17 random.tw. (40490)
18 control.tw. (314333)
19 double-blind.tw. (17824)
20 clinical trials/ (7555)
21 placebo/ (3760)
22 exp Treatment/ (578758)
23 or/17-22 (883642)
24 16 and 23 (21)
25 limit 24 to yr=“2013 -Current” (2)
Appendix 6. CINAHL search strategy (20 May 2014)
# Query Results
S27 S14 AND S26 117
S26 S22 AND S25 345
S25 S23 OR S24 1,505
S24 (MH “Ovarian Hyperstimulation Syndrome”) OR “ovarian
hyperstimulation syndrome”
202
S23 TX ovulat* 1,373
S22 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 450,401
S21 TX echograph* 173
S20 TX Measur* 350,807
S19 TX scanned 1,212
S18 TX scanning 6,423
S17 TX scan 12,299
S16 TX monitor* 82,820
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(Continued)
S15 (MH “Ultrasonography, Prenatal”) OR (MH “Ultrasonogra-
phy”) OR “ultrasound”
31,069
S14 S1 OR S2 or S3 or S4 OR S5 OR S6 OR S7 OR S8 OR S9
OR S10 OR S11 OR S12 OR S13
Display
S13 TX allocat* random* Display
S12 (MH “Quantitative Studies”) Display
S11 (MH “Placebos”) Display
S10 TX placebo* Display
S9 TX random* allocat* Display
S8 (MH “Random Assignment”) Display
S7 TX randomi* control* trial* Display
S6 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl*
n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1
mask*) )
Display
S5 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) Display
S4 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) Display
S3 TX clinic* n1 trial* Display
S2 PT Clinical trial Display
S1 (MH “Clinical Trials+”) Display
WH A T ’ S N E W
Last assessed as up-to-date: 30 May 2014.
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Date Event Description
30 May 2014 New citation required but conclusions have not changed New studies included and summary of findings table
added.
30 May 2014 New search has been performed Four studies added to the review (Aguirre 2010;Rongieres
2006; Strawn 2007; Wiser 2012).
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 2, 2008
Date Event Description
15 December 2013 New citation required and conclusions have changed Substantive amendment
7 November 2008 New search has been performed Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
IK took the lead in writing the draft of the protocol, developed the intended methods of the review, was involved in selecting trials for
inclusion, performed independent data extraction and quality assessment of included trials, contacted authors for additional information
and was responsible for statistical analyses, and writing the final review.
SB helped to develop the protocol and intended methods of the review, was consultant on clinical issues, made significant contributions
to the interpretation of results and improvement of the final review.
AW and AK were involved in selecting trials for inclusion, contacting authors for additional information, performed independent data
extraction and quality assessment of included trials. AW contributed to the statistical analyses and interpretation of results, provided
clinical input and helped to write the final review.
D E C L A R A T I O N S O F I N T E R E S T
None known
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S O U R C E S O F S U P P O R T
Internal sources
• Review authors, Other.
The review authors had no specific funding for this review
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Fertilization in Vitro; Biological Markers [blood]; Estradiol [∗blood]; Live Birth; Ovarian Hyperstimulation Syndrome [∗diagnosis;
ultrasonography]; Ovulation Induction [∗methods]; Pregnancy Rate; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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